A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

被引：0
|
作者：
Noelle K. LoConte
James P. Thomas
Dona Alberti
Jennifer Heideman
Kimberly Binger
Rebecca Marnocha
Kyle Utecht
Peter Geiger
Jens Eickhoff
George Wilding
Jill Kolesar
机构：
[1] University of Wisconsin Paul P. Carbone Comprehensive Cancer Center,
[2] The Ohio State University Comprehensive Cancer Center,undefined
[3] University of Wisconsin School of Pharmacy,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 63卷
关键词：
Bortezomib; Doxorubicin; Ubiquitination; Proteasome inhibition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [31] Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial
    Onda, T
    Katsumata, N
    Tsunematsu, R
    Yasugi, T
    Mushika, M
    Yamamoto, K
    Fujii, T
    Hirakawa, T
    Kamura, T
    Saito, T
    Yoshikawa, H
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (09) : 540 - 546
  • [32] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Kumar, Shaji K.
    Jett, James
    Marks, Randolph
    Richardson, Ronald
    Quevedo, Fernando
    Moynihan, Timothy
    Croghan, Gary
    Markovic, Svetomir N.
    Bible, Keith C.
    Qin, Rui
    Tan, Angelina
    Molina, Julian
    Kaufmann, Scott H.
    Erlichman, Charles
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1201 - 1206
  • [33] Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial
    Yang, TS
    Wang, CH
    Hsieh, RK
    Chen, JS
    Fung, MC
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1771 - 1778
  • [34] Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Traynor, Anne M.
    Thomas, James P.
    Ramanathan, Ramesh K.
    Mody, Tarak D.
    Alberti, Dona
    Wilding, George
    Bailey, Howard H.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (02) : 316 - 322
  • [35] Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M. Traynor
    James P. Thomas
    Ramesh K. Ramanathan
    Tarak D. Mody
    Dona Alberti
    George Wilding
    Howard H. Bailey
    Investigational New Drugs, 2011, 29 : 316 - 322
  • [36] A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    Tanios Bekaii-Saab
    Larry J. Schaaf
    Gregory B. Lesinski
    David M. Lucas
    Donn C. Young
    Amy S. Ruppert
    John C. Byrd
    Kristy Culler
    Diedre Wilkins
    John J. Wright
    Michael R. Grever
    Charles L. Shapiro
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 151 - 158
  • [37] A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Ramaswamy, Bhuvaneswari
    Bekaii-Saab, Tanios
    Schaaf, Larry J.
    Lesinski, Gregory B.
    Lucas, David M.
    Young, Donn C.
    Ruppert, Amy S.
    Byrd, John C.
    Culler, Kristy
    Wilkins, Diedre
    Wright, John J.
    Grever, Michael R.
    Shapiro, Charles L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 151 - 158
  • [38] A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
    J. Portnow
    P. Frankel
    S. Koehler
    P. Twardowski
    S. Shibata
    C. Martel
    R. Morgan
    M. Cristea
    W. Chow
    D. Lim
    V. Chung
    K. Reckamp
    L. Leong
    T. W. Synold
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 505 - 514
  • [39] A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
    Portnow, J.
    Frankel, P.
    Koehler, S.
    Twardowski, P.
    Shibata, S.
    Martel, C.
    Morgan, R.
    Cristea, M.
    Chow, W.
    Lim, D.
    Chung, V.
    Reckamp, K.
    Leong, L.
    Synold, T. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 505 - 514
  • [40] A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma
    Takamatsu, Yasushi
    Sunami, Kazutaka
    Hata, Hiroyuki
    Nagafuji, Koji
    Choi, Ilseung
    Higuchi, Masakazu
    Uozumi, Kimiharu
    Masaki, Yasufumi
    Tamura, Kazuo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 503 - 509
12345